Investigating alternative treatments for non-reponsive lymphoma patients
Mathias J Rummel
Highlights from the 2016 European Multiple Myeloma Academy (EMMA) and overview of EMMA 2017
Jesús San Miguel
Making the market more competitive - the potential benefit of biosimilars
How to address the issue of access to new drugs in multiple myeloma
Paul Richardson et al.
The real cost of hematological cancer care explained